The CE marking on a medical device is the manufacturer's declaration under Article 20 of MDR (or Article 18 of IVDR) that the device meets all applicable EU requirements, including the General Safety and Performance Requirements of Annex I, and has undergone the applicable conformity assessment procedure. It permits placing the device on the market throughout the European Economic Area, Switzerland (via MRA), and Turkey.

Why it matters

For Class I (non-sterile, non-measuring, non-reusable surgical) devices, the manufacturer self-certifies. For all higher classes, a Notified Body is involved and its four-digit identification number appears next to the CE mark (e.g. CE 0123 for TUV SUD). CE marking must be affixed visibly, legibly, and indelibly to the device and packaging, and reproduced in the IFU. Brexit split the market: Great Britain requires UKCA (or continues to accept CE until 30 June 2030 under the UK MDR (Amendment) Regulations 2023), while Northern Ireland continues to use CE under the Windsor Framework. The EU Declaration of Conformity (Annex IV of MDR) must accompany the device and reference the applicable regulation, the Notified Body if involved, and harmonized standards used.

Common pitfalls

•Affixing CE mark before the Notified Body issues the certificate for Class IIa+ - illegal placing on the market.
•Using the CE mark for a device not covered by the Notified Body scope or for indications outside the certificate.
•Missing the mandatory dimensions (minimum 5 mm height) or altering the proportions specified in Annex V of Regulation 765/2008.
•Assuming CE for a medical device also covers Machinery Directive, EMC Directive, or RED requirements - each applicable EU legislation must be assessed separately and cited in the DoC.

Sources

CE Marking (European Commission) · European Commission
MDR Article 20 (CE marking) · EUR-Lex
Regulation (EC) 765/2008 (CE mark rules) · EUR-Lex

Open full page

Regulatory

MHRA / UKCA Marking(MHRA / UKCA)

In one line

UK regulator and post-Brexit conformity marking for medical devices in Great Britain.

Definition

The Medicines and Healthcare products Regulatory Agency (MHRA) regulates devices in Great Britain under the UK MDR 2002 (as amended). UKCA marking will replace CE marking for the GB market on a transition timeline currently extended through 2030 for many device classes. Great Britain (England, Scotland and Wales) uses the UK Medical Devices Regulations 2002, while Northern Ireland follows EU rules under the Windsor Framework. Devices must be registered with the MHRA, and non-UK manufacturers need a UK Responsible Person. Legislation allows CE-marked devices to continue to be placed on the Great Britain market until 2028 or 2030 depending on device type and certificate, while the UK finalizes its new framework.

Why it matters

Northern Ireland continues to follow EU rules under the Windsor Framework, requiring CE/UKNI marks. UK Approved Bodies - separate from EU Notified Bodies - perform conformity assessments for UKCA.

Common pitfalls

•Failing to understand the extended transition timelines for UKCA marking can lead to non-compliance for devices placed on the Great Britain market.
•Confusing the requirements for UKCA marking with CE marking, which applies in the EU and Northern Ireland, can result in incorrect conformity assessments.
•Not engaging with a UK Approved Body for higher-risk devices requiring third-party conformity assessment under UKCA regulations is a common pitfall.
•Assuming that a device with a CE mark can automatically be placed on the Great Britain market without considering any additional UKCA specific requirements, even during the transition period.
•Overlooking the specific requirements for economic operators, such as UK Responsible Persons, when marketing devices in Great Britain under UKCA regulations.

Sources

Open full page

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.